( September 10, 2026, 2:58 PM EDT) -- NEW YORK — A federal judge in New York dismissed investors’ putative class action against a clinical biopharmaceutical company and certain of its senior officers and board members for making allegedly false and misleading statements about a clinical trial of the company’s flagship product, holding that the investors failed to identify an actionable false statement....